neutral
11h agoTop IPO Listing: Corona Remedies debuts with 38% premium, delivers strong gains to investors
Corona Remedies made a powerful entry into the secondary market on December 15, listing at ₹1,470 on the NSE and ₹1,452 on the BSE, marking gains of over 36–38 percent against the IPO price of ₹1,062. The ₹655.68-crore offer-for-sale issue was heavily oversubscribed across all categories, reflecting strong confidence in the company’s therapeutic focus and profitability. Investors earned ₹20,580 per lot, while the company entered markets with a healthy balance sheet and consistent earnings growth.
neutral
11h agoTop IPO Listing: Corona Remedies debuts with 38% premium, delivers strong gains to investors
Corona Remedies made a powerful entry into the secondary market on December 15, listing at ₹1,470 on the NSE and ₹1,452 on the BSE, marking gains of over 36–38 percent against the IPO price of ₹1,062. The ₹655.68-crore offer-for-sale issue was heavily oversubscribed across all categories, reflecting strong confidence in the company’s therapeutic focus and profitability. Investors earned ₹20,580 per lot, while the company entered markets with a healthy balance sheet and consistent earnings growth.
Recently
1 min read
77 words
Corona Remedies delivered a stellar stock market debut with over 38 percent listing gains, rewarding IPO investors amid strong institutional demand and robust financial performance.
Corona Remedies made a powerful entry into the secondary market on December 15, listing at ₹1,470 on the NSE and ₹1,452 on the BSE, marking gains of over 36–38 percent against the IPO price of ₹1,062. The ₹655.68-crore offer-for-sale issue was heavily oversubscribed across all categories, reflecting strong confidence in the company’s therapeutic focus and profitability. Investors earned ₹20,580 per lot, while the company entered markets with a healthy balance sheet and consistent earnings growth.
Corona Remedies made a powerful entry into the secondary market on December 15, listing at ₹1,470 on the NSE and ₹1,452 on the BSE, marking gains of over 36–38 percent against the IPO price of ₹1,062. The ₹655.68-crore offer-for-sale issue was heavily oversubscribed across all categories, reflecting strong confidence in the company’s therapeutic focus and profitability. Investors earned ₹20,580 per lot, while the company entered markets with a healthy balance sheet and consistent earnings growth.
Dec 15, 2025 • 10:10